CompletedPhase 1NCT00011414
Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors
Studying Nephroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Brigitte C Widemann, M.D.National Cancer Institute (NCI)
- Intervention
- Tariquidar(drug)
- Enrollment
- 29 enrolled
- Eligibility
- 2-18 years · All sexes
- Timeline
- 2001 – 2016
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00011414 on ClinicalTrials.govOther trials for Nephroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06401330A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)Children's Oncology Group
- RECRUITINGPHASE2NCT05985161A Study of Selinexor in People With Wilms Tumors and Other Solid TumorsMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT05384821Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)Centre Oscar Lambret
- RECRUITINGPHASE2NCT04968990Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam IrradiationSt. Jude Children's Research Hospital
- RECRUITINGNCT04423484Therapeutic Recommendations for NephroblastomaFrench Africa Pediatric Oncology Group